QT Holdings reports findings from breast quantitative imaging biomarker study

QT Holdings has announced the completion of a study evaluating a breast quantitative imaging biomarker; the firm has not yet disclosed specific sensitivity, specificity, or clinical endpoints.

• Source is a trade publication reporting a company announcement; study design, sample size, and endpoints not provided.
• Limited details available; findings have not been peer-reviewed or externally validated.
• Potential impact on breast imaging practice remains uncertain pending full data release.

RadPigeon summaries are original and for information only. They are not clinical advice.